SCHEMBL8076206

SCHEMBL8076206

CCc1cccc2[nH]c(-c3nc(C4CCN(C(=O)c5ccsc5)CC4)n4ccnc(N)c34)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 2/20 0.57
SRC P12931 2/20 0.57
ABL1 P00519 2/20 0.51
IGF1R P08069 2/20 0.51
PDPK1 O15530 1/20 0.51
EGFR P00533 1/20 0.51
INSR P06213 1/20 0.51
KDR P35968 1/20 0.51
MAP2K1 Q02750 1/20 0.51
FGFR1 P11362 1/20 0.46
PIK3CA P42336 1/20 0.46
PIK3CB P42338 1/20 0.46
MTOR P42345 1/20 0.46
PIK3CG P48736 1/20 0.46
PRKDC P78527 1/20 0.46
RICTOR Q6R327 1/20 0.46
RPTOR Q8N122 1/20 0.46
MAPKAP1 Q9BPZ7 1/20 0.46
MLST8 Q9BVC4 1/20 0.46
TNK2 Q07912 11/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8074237 0.94 RAF1 (0.55) RAF1SRCABL1IGF1RPDPK1
SCHEMBL6940765 0.91 RAF1 (0.58) RAF1SRCABL1IGF1RPDPK1
SCHEMBL6942755 0.91 RAF1 (0.57) RAF1SRCABL1IGF1RPDPK1
SCHEMBL6941933 0.90 RAF1 (0.56) RAF1SRCABL1IGF1RPDPK1
SCHEMBL6939043 0.89 RAF1 (0.55) RAF1SRCABL1IGF1RPDPK1
SCHEMBL6940860 0.89 PIK3CA (0.56) RAF1SRCABL1IGF1RPDPK1
SCHEMBL6943204 0.88 RAF1 (0.55) RAF1SRCABL1IGF1RPDPK1
SCHEMBL6942301 0.88 RAF1 (0.55) RAF1SRCABL1IGF1RPDPK1
SCHEMBL595244 0.88 RAF1 (0.71) RAF1SRCABL1IGF1RPDPK1
SCHEMBL8066085 0.88 RAF1 (0.48) RAF1SRCABL1IGF1RPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 US disclosed
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163468-A1 Fused Bicyclic mTor Inhibitors MTOR, RICTOR, MAPKAP1 RAF1 260/4885SRC 294/4885ABL1 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.